Mocht u de informatie op onze website kanker-actueel.nl waarderen dan wilt u ons misschien ondersteunen met een donatie

Ons rekeningnummer is: RABO 37.29.31.138 t.n.v. Stichting Gezondheid Actueel in Terneuzen. 

Onze IBANcode is NL79 RABO 0372 9311 38

Als donateur kunt u ook korting krijgen bij verschillende bedrijven.

En we hebben een ANBI status

Raadpleeg altijd een goed gekwalificeerd complementair werkend arts.

17 december 2019: Zie ook dit artikel: 

https://kanker-actueel.nl/car-t-celtherapie-met-het-b-cell-maturation-antigen-bcma-geeft-alsnog-complete-remissies-bij-meer-dan-de-helft-van-de-18-geselecteerde-zwaar-voorbehandelde-patienten-met-vergevorderde-multiple-myeloma-kahler.html

17 december 2019: Bron: American Society of Hematology - ASH 2019

Gisteren vroegen we nog aandacht voor de brief over CAR-T cel behandelingen n.a.v. de brief van een aantal top wetenschappers. 

Vandaag een studiepublicatie over de toepassing van een vorm van CAR-T celtherapie bij patienten met vergevorderde myeloma (botkanker - Kahler)  met hele goede resultaten. Maar liefst 95 procent van de 29 deelnemende patienten met vergevorderde en zwaar voorbehandelde multiple myeloma reageerden uitstekend op deze behandeling. Waarvan maar liefst 67 procent met een complete remissie. 

Zie studieprotocol: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1)

Uit het abstract:

Resultaten van het fase 1b-gedeelte van het CARTITUDE-1-onderzoek vertoonden snelle en duurzame reacties bij patiënten (n = 29) met een mediaan van vijf eerdere behandelingen met multiple myeloma (bereik, 3-18) behandeld met JNJ-4528 (mediane toegediende dosis 0,73x106 CAR + levensvatbare T-cellen / kg), waarbij:

  • 100 procent van de patiënten een respons bereikte (95 procent betrouwbaarheidsinterval , 76-95) bij een mediane follow-up van zes maanden.
  • Het totale responspercentage (ORR) bedroeg 69 procent van de patiënten die een volledige remissie (CR) of beter bereikten (66 procent die een duurzame CR bereikte);
  • 86 procent van de patiënten die een zeer goede gedeeltelijke respons (VGPR) of beter bereikten;
  • en 14 procent van de patiënten die een gedeeltelijke respons (PR) bereikten.
  • Bovendien bereikte 100 procent van de evalueerbare patiënten vroege minimale residuele ziekte (MRD) - negatieve ziektestatus op dag 28 na de infusie.

Bij de follow-up van zes maanden waren 27 van de 29 patiënten zonder progressie. Op basis van de resultaten van fase 1b werd een aanbevolen dosis van fase 2 van 0,75x106 CAR + levensvatbare T-cellen / kg bevestigd.

Zie in dit artikel hoe CAR-T cellen werken en stand van zaken.

Hier het abstract van de studie zoals vermeld in een persbericht van de producent en gepresenteerd op de ASH 2019 afgelopen week. 

Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma

577 Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma: Therapy, excluding Transplantation: Novelty in CAR T in Relapsed/Refractory Multiple Myeloma
Hematology Disease Topics & Pathways:
Diseases, Biological, Adult, multiple myeloma, Therapies, CAR-Ts, white blood cells, Cell Lineage, Plasma Cell Disorders, Study Population, Lymphoid Malignancies, Clinically relevant
Monday, December 9, 2019: 7:00 AM
Hall D, Level 2 (Orange County Convention Center)

Deepu Madduri, MD1*, Saad Z. Usmani, MD2, Sundar Jagannath3*, Indrajeet Singh, PhD4*, Enrique Zudaire, PhD4*, Tzu-Min Yeh5*, Alicia J. Allred, PhD4*, Arnob Banerjee, MD4*, Jenna D. Goldberg, MD5*, Jordan M Schecter, MD5, Sen Zhuang5*, Jeffrey R. Infante, MD4*, Syed Rizvi6*, Xiaohu (Frank) Fan, MD, PhD6*, Andrzej Jakubowiak, MD, PhD7 and Jesus G. Berdeja, MD8

1Icahn School of Medicine at Mount Sinai, New York, NY
2Levine Cancer Institute, Atrium Health, Charlotte, NC
3Mount Sinai Medical Center, New York, NY
4Janssen R&D, Spring House, PA
5Janssen R&D, Raritan, NJ
6Legend Biotech USA, Piscataway, NJ
7University of Chicago, Chicago, IL
8Sarah Cannon Research Institute, Nashville, TN

JNJ-68284528 (JNJ-4528) is a chimeric antigen receptor T cell (CAR-T) therapy containing two BCMA-targeting single-domain antibodies designed to confer avidity. A first-in-human phase 1 study (LEGEND-2) conducted in China of LCAR-B38M, an identical CAR to JNJ-4528, showed high overall response and manageable safety in 74 patients (pts) with R/R MM. Phase 1b results from the ongoing CARTITUDE-1 study conducted in the US with JNJ-4528 are presented here (NCT03548207).

Eligible pts (≥18 years) were diagnosed with MM per International Myeloma Working Group (IMWG) criteria, had measurable disease as assessed by M-protein or serum free light chain levels, received ≥3 prior regimens or were double refractory to a proteasome inhibitor (PI) and immunomodulatory drug (IMiD), and received an anti-CD38 antibody. Bridging therapy was allowed after apheresis. Cyclophosphamide 300 mg/m2 and fludarabine 30 mg/mover 3 days were used as the conditioning regimen. A single infusion of JNJ-4528 at the targeted 0.75x106 CAR+ cells/kg (target range 0.5–1.0x106) dose was administered 5–7 days after the start of the conditioning regimen. Primary objectives for phase 1b were to characterize the safety of JNJ-4528 and confirm the recommended phase 2 dose (RP2D).

Adverse events (AEs) were graded using CTCAE, v5.0, cytokine release syndrome (CRS) using Lee et al. (Blood 2014;124:188), and neurotoxicity using both CTCAE, v5.0 and the ASTCT grading system (Lee et al. Biol Blood Marrow Transplant 2019 25(4):625). Response was assessed per IMWG criteria, and minimal residual disease (MRD) was assessed by next generation flow cytometry and/or next generation sequencing.

As of 24 Jun 2019, 25 pts had been infused with JNJ-4528 in the phase 1b portion of the study. Median age was 61 years (range 50–75), pts had received a median of 5 (range 3–16) prior lines of treatment, 88% were triple-refractory to a PI, IMiD, and anti-CD38 antibody, 72% were penta-exposed, and 36% were penta-refractory. The median administered dose was 0.73x106 CAR+ cells/kg (range 0.5–0.9x106).

Most frequently reported AEs were CRS (88%), neutropenia (80%), anemia (76%), and thrombocytopenia (72%). Hematologic AEs of grade ≥3 included neutropenia (76%), thrombocytopenia (60%), and anemia (48%). The majority of pts (80%) had grade 1–2 CRS, with 1 grade 3 event and 1 grade 5 event at day 99 from sequalae of grade 4 CRS (dose-limiting toxicity).

CRS events had a generally predictable time to onset, occurring at a median of 7 days (range 2–12) post-infusion with a median duration of 4 days (range 1–60). Tocilizumab and corticosteroids were administered in 91% and 27% of pts with CRS (n=22), respectively. Three pts had CAR-T-related neurotoxicity of grade 1 (n=2) and grade 3 (n=1); all events occurred in the context of CRS and resolved within 1–2 days.

At data cut-off, 21 pts were evaluable for response (postbaseline evaluation at day 28) with a median follow-up of 3 months (range 1–10). Reduction in tumor burden was observed for all pts (Figure). An overall response rate of 91% was observed, with 4 stringent complete responses (sCRs), 2 CRs, 7 very good partial responses, and 6 partial responses. Of the 15 pts with post-infusion day 28 evaluable bone marrow (BM) samples, 10 were MRD-negative at the 10-5 sensitivity level, 2 at the 10-4 sensitivity level, and 3 had unidentified clones. No pts had progressed at the time of data cutoff. Responses were independent of baseline BCMA expression.

JNJ-4528 CAR+ cellular and transgene levels showed expansion and persistence in both blood and BM, with peak expansion 9–14 days after dosing in a majority of pts. All pts showed similar kinetics of decline in soluble BCMA (sBCMA) levels, and continued depletion in sBCMA suggests CAR-T-mediated pharmacodynamic activity. Serum cytokine levels (i.e., IL-6, IFNγ, IL-10) increased post-infusion and peaked around day 10, coinciding with peak expansion of CAR+ T cells. Increases in some proinflammatory cytokines (i.e., IL-6) correlated with onset of CRS symptoms.

Collectively these results demonstrate that JNJ-4528 at a target dose of 0.75x106 CAR+ cells/kg delivers early and deep responses, including MRD negativity in all evaluable pts tested, with a manageable safety profile in pts with refractory MM. The safety and efficacy results from the ongoing CARTITUDE-1 study are consistent with the LEGEND-2 study and confirm the 0.75x106 CAR+ cells/kg dose as the RP2D for further clinical development.

Disclosures: Madduri: Takeda: Consultancy; Foundation Medicine: Consultancy; AbbVie: Consultancy; Celgene: Consultancy; Janssen: Consultancy. Usmani: Amgen Array Biopharma, Bristol-Myers Squibb, Celgene, Janssen, Merck, Pharmacyclics, Sanofi, Takeda: Other: Research Grant; Amgen, Celgene, Janssen, Sanofi, Takeda: Speakers Bureau; Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck, SkylineDX, Takeda: Other: Consultant/Advisor. Jagannath: AbbVie: Consultancy; Karyopharm Therapeutics: Consultancy; Bristol-Myers Squibb: Consultancy; Celgene Corporation: Consultancy; Janssen Pharmaceuticals: Consultancy; Merck & Co.: Consultancy. Singh: Janssen R&D: Employment, Equity Ownership. Zudaire: Janssen R&D: Employment, Equity Ownership. Yeh: Janssen R&D: Employment, Equity Ownership. Allred: Janssen R&D: Employment, Equity Ownership. Banerjee: Janssen R&D: Employment, Equity Ownership. Goldberg: Janssen R&D: Employment, Equity Ownership. Schecter: Janssen R&D, LLC: Employment, Equity Ownership. Zhuang: Janssen R&D: Employment, Equity Ownership. Infante: Janssen R&D: Employment, Equity Ownership. Rizvi: Legend Biotech: Employment, Equity Ownership. Fan: Legend Biotech: Employment, Equity Ownership. Jakubowiak: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Juno: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Millennium: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; SkyLineDx: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Consultancy, Honoraria; KaryoPharm Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Berdeja: Amgen Inc, BioClinica, Celgene Corporation, CRISPR Therapeutics, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, Kite Pharma Inc, Prothena, Servier, Takeda Oncology: Consultancy; AbbVie Inc, Amgen Inc, Acetylon Pharmaceuticals Inc, Bluebird Bio, Bristol-Myers Squibb Company, Celgene Corporation, Constellation Pharma, Curis Inc, Genentech, Glenmark Pharmaceuticals, Janssen Biotech Inc, Kesios Therapeutics, Lilly, Novartis, Poseida: Research Funding; Poseida: Research Funding.


Plaats een reactie ...

Reageer op "JNJ-4528 is een vorm van CAR-T cel behandeling en geeft uitstekende resultaten met 67 procent duurzame complete remissie in nieuwe studie bij uitbehandelde patienten met vergevorderde en zwaar voorbehandelde multiple myeloma"


Gerelateerde artikelen
 

Gerelateerde artikelen

JNJ-4528 is een vorm van CAR-T >> CAR T-celtherapie met het >>